

Ormutivimab

Cat. No.:	HY-P99792
CAS No.:	2449086-91-1
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model ^[1] ^[2] .	
In Vivo	Ormutivimab (20 IU/kg; i.m.; single dose) protects beagles from a lethal challenge of street RABV BD06 ^[1] . Ormutivimab (20 IU/kg, 100 IU/kg; i.m.; single dose) protects challenged Kunming mice against various rabies virus ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Balb/c mice challenge model with rabies virus ^[1]
	Dosage:	20 IU/kg, 100 IU/kg
	Administration:	Intramuscular injection; single dose after 4 hr after infection
	Result:	Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.

REFERENCES

- [1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267.
- [2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA